Oliver Aasmets
https://www.etis.ee/CV/Oliver_Aasmets/eng
17.09.1993
oliver.aasmets@ut.ee
Career
Institutions and positions
01.01.2021–30.09.2024
University of Tartu, Faculty of Science and Technology, Institute of Genomics, Specialist (0,30)
01.09.2020–31.12.2020
University of Tartu, Institute of Genomics, Specialist (0,30)
01.10.2019–31.08.2020
University of Tartu, Institute of Genomics, Specialist (0,10)
Education
2012–30.06.2015
University of Tartu, mathematical statistics, bachelor studies
Qualifications
Academic degrees
Projects in progress
29.10.2020
Oliver Aasmets
https://www.etis.ee/CV/Oliver_Aasmets/est
17.09.1993
oliver.aasmets@ut.ee
Teenistuskäik
Töökohad ja ametid
01.01.2021–30.09.2024
Tartu Ülikool, Loodus- ja täppisteaduste valdkond, genoomika instituut, spetsialist (0,30)
01.09.2020–31.12.2020
Tartu Ülikool, Tartu Ülikooli genoomika instituut, spetsialist (0,30)
01.10.2019–31.08.2020
Tartu Ülikool, Tartu Ülikooli genoomika instituut, spetsialist (0,10)
Haridustee
2012–30.06.2015
Tartu Ülikool, matemaatilise statistika bakalaureuseõpe
Kvalifikatsioon
Teaduskraadid
Jooksvad projektid
29.10.2020
Search project
Institution is projects' financier
Institution is projects' executor
All
Projects
Master projects
Subprojects
New Frascati (2015)
Old and new Frascati
All
Ongoing
Finished
Beginning
Fuzzy
Precise
- Found 3 results
Program | Type | Number | Name | Project start | Project end | Principal investigator | Institution | Financing | |
---|---|---|---|---|---|---|---|---|---|
TK | SLTMR16142T (TK142) | Centre of Excellence for Genomics and Translational Medicine (TK142) | 01.01.2016 | 01.03.2023 | Andres Metspalu | University of Tartu, Estonian Genome Center | 4 474 349,50 EUR | ||
PUT; PUT_SP | PUT1371 | The interplay between gut microbiota and metformin treatment in type 2 diabetes through bile acid metabolism | 01.01.2017 | 31.10.2021 | Elin Org | University of Tartu, Estonian Genome Center ; University of Tartu, Institute of Genomics | 222 244,00 EUR | ||
1.2.1.3.2.6. | MP1GI21013 (S-BMT-21-11 (LT08-2-LMT-K-01-060)) | Gut-blood-liver axis: Circulating microbiome as non-invasive biomarker for Inflammatory bowel disease (IBD) and Primary sclerosing cholangitis (PSC) | 01.01.2021 | 31.12.2023 | Elin Org | University of Tartu, Institute of Genomics | 130 000,00 EUR |